Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 1/20 | 0.51 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.51 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.51 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | LATS1 | O95835 | 5/20 | 0.46 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | KDM4A | O75164 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38662207 | 0.90 | CACNA1H (0.54) | CACNA1HCACNA1BCACNA1CBCHELATS1 | |
| SCHEMBL4085766 | 0.90 | CACNA1H (0.54) | CACNA1HCACNA1BCACNA1CBCHELATS1 | |
| SCHEMBL29893017 | 0.85 | KDM4C (0.54) | CACNA1HCACNA1BCACNA1CLATS1LATS2 | |
| SCHEMBL6297783 | 0.84 | BCHE (0.65) | CACNA1HCACNA1BCACNA1CBCHEPTPN1 | |
| SCHEMBL30313258 | 0.81 | CACNA1H (0.54) | CACNA1HCACNA1BCACNA1CBCHEPTPN1 | |
| SCHEMBL27140579 | 0.80 | SMN1; SMN2 (0.45) | TSHRMAPK10ROCK1KMT2APOLB | |
| SCHEMBL22775707 | 0.80 | CACNA1H (0.53) | CACNA1HCACNA1BCACNA1CBCHEPTPN1 | |
| SCHEMBL22013237 | 0.80 | CACNA1H (0.53) | CACNA1HCACNA1BCACNA1CBCHEPTPN1 | |
| SCHEMBL29613729 | 0.80 | CACNA1H (0.53) | CACNA1HCACNA1BCACNA1CBCHEPTPN1 | |
| SCHEMBL4149629 | 0.80 | CACNA1H (0.53) | CACNA1HCACNA1BCACNA1CBCHEPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026101698-A1 | HEPCIDIN MIMETIC COMPOUNDS AND USES THEREOF | PROTAGONIST THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20260062443-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMA INC (US) | 2026-03-05 | — | — | US | disclosed |
| WO-2024044098-A2 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062443-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | C9, SSB, C1S | CACNA1H 2691/4885CACNA1B 2526/4885CACNA1C 2116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.